Alivus Life Sciences Files Integrated Annual Report FY 2025-26

Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Ltd) has submitted its Integrated Annual Report for the Financial Year 2025-26, in compliance with SEBI LODR Regulations. The report, prepared according to the Integrated Reporting Framework and GRI standards, offers a holistic view of the company's strategy, governance, performance, and outlook, emphasizing value creation across six capitals: Financial, Manufactured, Intellectual, Human, Social & Relationship, and Natural. The report covers both financial and non-financial performance from April 1, 2025, to March 31, 2026. Alivus is leveraging its expertise in chemistry and manufacturing to expand into adjacent business areas, aiming to enhance its portfolio and customer relationships. The company has obtained independent assurance for its BRSR Core KPIs from BSI.